A plain-language guide

autosomal dominant polycystic kidney disease

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Early map · 8 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. autosomal dominant polycystic kidney disease is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's autosomal dominant polycystic kidney disease?

Autosomal dominant polycystic kidney disease is the most common inherited kidney disorder. Multiple cysts develop in both kidneys and enlarge over time, and kidney function gradually declines.

Features mapped6
Treatments mapped1
Published sources6
Last reviewed2026-08-04

Signs and symptoms

Hematuria

Blood in the urine (hematuria) can occur in ADPKD.

Limited evidenceSource: PMID:42315404
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:730
Notesplain_language confirmed from PMID:42315404 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:730 -> PMID:42315404 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Hypertension

High blood pressure (hypertension) is one of the most common findings in ADPKD.

Limited evidenceSource: PMID:41907239
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42035037, ORPHA:730
Notesplain_language confirmed from PMID:42035037 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:730 -> PMID:41907239 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Enlarged kidney

The kidneys often become enlarged in ADPKD, and this can cause significant symptoms.

Limited evidenceSource: PMID:42212578
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:730
Notesplain_language confirmed from PMID:42212578 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:730 -> PMID:42212578 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Renal cyst

In ADPKD, many fluid-filled cysts develop and grow in both kidneys over time; their gradual buildup is the central feature of the disease.

Limited evidenceCurated reference: ORPHA:730
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42396661
Notesplain_language confirmed from PMID:42396661 via curation 2026-07-03 [llm:fable-5].
Last reviewed2026-07-03

Hepatic cysts

Cysts in the liver (hepatic cysts) are among the most common findings in ADPKD.

Limited evidenceSource: PMID:42035037
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:730
Notesplain_language confirmed from PMID:42035037 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:730 -> PMID:42035037 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Flank pain

Pain in the side or back (flank pain) can occur in ADPKD.

Limited evidenceSource: PMID:42315404
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:730
Notesplain_language confirmed from PMID:42315404 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:730 -> PMID:42315404 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

tolvaptan

Tolvaptan is a disease-modifying medicine for ADPKD that slows the growth in kidney size and the decline in kidney function, though it can have side effects.

Used to help with: Enlarged kidney.

Limited evidenceSource: PMID:42331437
The source text this rests on
“Tolvaptan, the only disease-modifying therapy, slows total kidney volume growth and estimated glomerular filtration rate decline in rapidly progressing cases, although it may have adverse effects.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42331437 via curation 2026-07-03
Last reviewed2026-07-03

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 6 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:730 · Orphanet/HPO annotations for Autosomal dominant polycystic kidney disease
PMID:41907239 · Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study.
PMID:42035037 · Association of 24-hour urinary parameters with renal function and other comorbidities in autosomal dominant polycystic kidney disease.
PMID:42212578 · Native nephrectomy in relation to kidney transplantation in autosomal dominant polycystic kidney disease patients; a narrative review of the literature.
PMID:42315404 · Autosomal dominant polycystic kidney disease: Current perspectives in 2026.
PMID:42331437 · Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treat

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.